BR0317384A - Combinações de valsartan com inibidores de cox-2 - Google Patents
Combinações de valsartan com inibidores de cox-2Info
- Publication number
- BR0317384A BR0317384A BR0317384-4A BR0317384A BR0317384A BR 0317384 A BR0317384 A BR 0317384A BR 0317384 A BR0317384 A BR 0317384A BR 0317384 A BR0317384 A BR 0317384A
- Authority
- BR
- Brazil
- Prior art keywords
- diabetic
- disease
- pharmaceutically acceptable
- valsartan
- cox
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 3
- 229940111134 coxibs Drugs 0.000 title abstract 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 3
- 229960004699 valsartan Drugs 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 4
- 208000010496 Heart Arrest Diseases 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 206010033557 Palpitations Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
- 208000032594 Vascular Remodeling Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMBINAçõES DE VALSARTAN COM INIBIDORES DE COX-2". A invenção refere-se a uma composição farmacêutica compreendendo uma combinação de (i) valsartan bloqueador de receptor de AT 1 ou um sal farmaceuticamente aceitável deste e (ii) um inibidor de COX-2 ou um sal farmaceuticamente aceitável deste e opcionalmente um veículo farmaceuticamente aceitável e a um método para o tratamento ou prevenção de uma condição ou doença selecionada a partir do grupo consistindo em hipertensão, parada cardíaca tal como (aguda e crónica) parada cardíaca congestiva, cardiomiopatia hipertrófica e disfunção ventricular esquerda, miopatia cardíaca diabética, arritmias supraventriculares e ventriculares, fibrilação atrial, palpitação atrial, remodelagem vascular prejudicial, infarto miocárdico e suas seq³elas, aterosclerose, angina (quer instável, quer estável), insuficiência renal (diabética e não-diabética), parada cardíaca, angina pectoris, diabetes, aldosteronismo secundário, hipertensão pulmonar primária e secundária, condições de insuficiência renal, tais como nefropatia diabética, glomerulonefrite, escleroderma, esclerose glomerular, proteinúria de doença renal primária, e também hipertensão vascular renal, retinopatia diabética, o controle de outros distúrbios vasculares, tais como enxaqueca, doença vascular periférica, doença de Raynaud, hiperplasia luminal, disfunção cognitiva (tal como Alzheimer), glaucoma e acidente vascular cerebral, compreendendo administração de uma quantidade terapeuticamente eficaz da composição farmacêutica a um mamífero com necessidade disso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43425002P | 2002-12-18 | 2002-12-18 | |
| PCT/EP2003/014406 WO2004054575A1 (en) | 2002-12-18 | 2003-12-17 | Combinations of valsartan with cox-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317384A true BR0317384A (pt) | 2005-11-16 |
Family
ID=32595267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317384-4A BR0317384A (pt) | 2002-12-18 | 2003-12-17 | Combinações de valsartan com inibidores de cox-2 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060079579A1 (pt) |
| EP (1) | EP1575581A1 (pt) |
| JP (1) | JP2006511542A (pt) |
| CN (1) | CN1726030A (pt) |
| AU (1) | AU2003294883A1 (pt) |
| BR (1) | BR0317384A (pt) |
| CA (1) | CA2506809A1 (pt) |
| WO (1) | WO2004054575A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002983A1 (en) * | 2004-07-06 | 2006-01-12 | Novartis Ag | Combination of organic compounds |
| EA012392B1 (ru) | 2004-12-24 | 2009-10-30 | Крка, Д.Д. Ново Место | Твердая фармацевтическая композиция, содержащая валсартан |
| CA2605183A1 (en) * | 2005-04-18 | 2006-10-26 | Rubicon Research Pvt. Ltd. | Bioenhanced compositions |
| JP2009532498A (ja) * | 2006-04-06 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の組合せ |
| EP2014284A1 (en) * | 2007-06-15 | 2009-01-14 | Novartis AG | Pharmaceutical compositions and uses |
| JP2011500577A (ja) * | 2007-10-09 | 2011-01-06 | ノバルティス アーゲー | バルサルタンの医薬製剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
-
2003
- 2003-12-17 EP EP03785857A patent/EP1575581A1/en not_active Withdrawn
- 2003-12-17 CA CA002506809A patent/CA2506809A1/en not_active Abandoned
- 2003-12-17 CN CNA2003801062310A patent/CN1726030A/zh active Pending
- 2003-12-17 JP JP2004560460A patent/JP2006511542A/ja active Pending
- 2003-12-17 AU AU2003294883A patent/AU2003294883A1/en not_active Abandoned
- 2003-12-17 BR BR0317384-4A patent/BR0317384A/pt not_active Application Discontinuation
- 2003-12-17 WO PCT/EP2003/014406 patent/WO2004054575A1/en not_active Application Discontinuation
- 2003-12-17 US US10/537,869 patent/US20060079579A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2506809A1 (en) | 2004-07-01 |
| AU2003294883A1 (en) | 2004-07-09 |
| CN1726030A (zh) | 2006-01-25 |
| EP1575581A1 (en) | 2005-09-21 |
| US20060079579A1 (en) | 2006-04-13 |
| WO2004054575A1 (en) | 2004-07-01 |
| JP2006511542A (ja) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0306907A (pt) | Composições farmacêuticas que compreendem valsartan e inibidores de nep | |
| WO2007106708A3 (en) | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril | |
| EP2322174A3 (en) | Combined use of valsartan and calcium channel blockers for therapeutic purposes | |
| HK1074774A1 (en) | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic | |
| WO2007045663A3 (en) | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure | |
| BR0317384A (pt) | Combinações de valsartan com inibidores de cox-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |